Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth
Bicara Therapeutics reported Q2 2026 financials and strategic leadership updates. Ryan Cohlhepp will become CEO in January 2027, succeeding Claire Mazumdar who will transition to Vice Chair and Strategic Advisor. The company is progressing enrollment for the pivotal FORTIFI-HN01 trial of its lead drug, ficerafusp alfa, targeting HPV-negative head a…